

PIRENZEPINE OPHTHALMIC GELRelated Applications

[0001] This application is a continuation and claims the benefit of priority of International Application No. PCT/US02/13823 filed May 1, 2002, designating the United States of America and published in English, which claims the benefit of priority of U.S. Provisional Application No. 60/293,731 filed May 25, 2001, both of which are hereby expressly incorporated by reference in their entireties.

Field of the Invention

[0002] The present invention is in the field of aqueous ophthalmic pharmaceutical formulations.

Background of the Invention

[0003] Myopia, axial elongation of the eye, affects a large proportion of the population. Commonly, the onset of myopia is during the grade school years and progresses until growth of the eye is completed. A pharmacologic therapy which prevents or retards the developmental abnormality of myopia would represent a major advance in the treatment of myopia.

[0004] The potential use for a pharmacologic therapy has been stimulated by evidence that atropine prevents the development of myopia in humans (D.A. Goss 1982 *Am J Optom Physiol Opt* **59**:828-841.), tree shrews (McKenna J.A. & V.A. Casagrande 1978 *Exp Eye Res* **26**:715-723.), stump-tailed monkeys and chicks (McBrien N.A. *et al.* 1991 *Biochem Soc Trans* **19**:861-865; McBrien N.A. *et al.* 1991 *Invest Ophthalmol Vis Sci* **32**:1203; Tigges M. *et al.* 1996 *Invest Ophthalmol Vis Sci* **37**:S326.). The clinical use of atropine as a therapy has been limited due to its ocular side effects including glare from pupillary dilation and blurred vision due to loss of accommodation. Mild cycloplegic agents like tropicamide have been effective in a number of studies but failed in other studies (Curtin B.J. & D.B. Karlin 1971 *Am J Ophthalmol* **71**:42-53.).

[0005] Stone and Laties found that subconjunctival injections of atropine, a nonselective muscarinic antagonist, and pirenzepine, a relatively selective M1-antagonist marketed for systemic use in Europe for its anti-dyspepsia properties, attenuated axial eye

growth in a chick model of myopia. M2 and M3 antagonists did not prevent axial elongation (Stone R.A. *et al.* 1991 *Exp Eye Res* **52**:755-758; U.S. Patent No. 5,112,522, Filed May 11, 1990). Unlike atropine, a selected concentration of pirenzepine may prevent myopia without inducing unwanted side effects such as disabling mydriasis and cycloplegia.

[0006] Pirenzepine is a relatively selective M1-muscarinic antagonist. It is being investigated for its topical ocular use to moderate and halt the progression of pediatric myopia. Administered as a solution in up to 2% strength, it was found comfortable and without systemic effects in adult volunteers (Shedden A.H. *et al.* 1998 *Invest Ophthalmol Vis Sci* **39**:S279.).

[0007] However, work on a solution dosage form of pirenzepine indicated a physical appearance problem. Pirenzepine is stable in solution especially at pH 5, but its degradation product is insoluble in water. Thus, the accumulation of even a small amount of degradation product over the shelf-life of the solution results in an unacceptable product due to the unattractive appearance of the precipitate in the solution.

[0008] There are no “standard” formulation solutions for such a problem. One approach is to use a refrigerated solution. Another approach is to use a lyophilized product for reconstitution prior to dispensing to the patient. However, neither of these approaches is optimal. Lyophilization adds considerably to the cost of the product and requires cumbersome reconstitution processes. Refrigeration is not always convenient. Thus, there is a need for pirenzepine in a dosage form that solves the physical appearance problem using a formulation approach that is deemed desirable.

Summary of the Invention


[0009] Accordingly, it is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier.

Detailed Description of the Preferred Embodiment

[0010] The ophthalmic aqueous gel formulation of the present invention for treating myopia comprises a pharmaceutically effective amount of pirenzepine in combination with a water soluble cellulose derivative.

[0011] The concentration of the pirenzepine in the present formulation may range from about 0.001 to 3% (w/v), preferably about 0.005 to 2% (w/v). Pirenzepine and its dihydrochloride salt are known in the art.

[0012] Below is the structure of pirenzepine dihydrochloride:



[0013] Molecular formula: C₁₉H₂₁N₅O₂•2 HCl•H₂O

[0014] Molecular weight: 442.3; 351.4 (anhydrous free base)

[0015] Chemical Names: 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-6H pyrido[2,3-b][1,4]-benzodiazepin-6-one dihydrochloride monohydrate
11-[(4-methyl-1-piperazinyl)acetyl]-pyrido[2,3-b][1,4]-benzodiazepin-6(5H)-one dihydrochloride monohydrate

[0016] Cellulose derivatives are used as gelling agents in the formulation of this invention. Most preferred is hydroxypropyl methylcellulose. Any cellulose derived gelling agent, however, that forms an aqueous gel at the desired viscosity, i.e., is soluble in water and forms a gel, can be used. Such derivatives are well known, as are their properties, and are described, e.g., in the U.S. Pharmacopeia (2000) (UNITED STATES PHARMACOPEIAL CONVENTION, INC., THE UNITED STATES PHARMACOPEIA/THE NATIONAL FORMULARY (2000)). Such gelling agents include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, and cellulose gum. Combinations of various derivatives may also be used. Cellulose based gelling agents are advantageous over, for example, cross-linked acrylic polymers. For example, Carbopol™, a cross-linked acrylic polymer, has been used to form an aqueous gel

containing pilocarpine hydrochloride for ophthalmic use. Cellulose based gelling agents, however, are less likely to cause adverse reactions.

[0017] The formulations of the invention are substantially viscous enough to form a viscous gel. The viscosity preferably is in the range of 10,000 to 300,000 centipoise (cps), most preferably 15,000-200,000 cps, at about 20°C and shear rate of 1s⁻¹ based on Brookfield RVDV analysis.

[0018] In the aqueous gel for ophthalmic use, the amount of cellulose based gelling agent is preferably from about 0.5 wt. % to 5 wt. %, most preferably from about 1 wt. % to 5 wt. %.

[0019] Suitable cellulose based preparations for use in the invention are commonly commercially available. For example, sources of hydroxypropyl methylcellulose that are suitable for making a cellulose based ophthalmic gel according to the invention include Ashland Distribution Co., Asiaamerica International Inc., Biddle Sawyer Corp., Carbomer Inc., Colorcon Inc., Dow Chemical Co., FOB Chemicals, Hercules Inc., Mutchler Inc., Penta Mfg Co., Spectrum Laboratory Products Inc., Van Waters & Rogers Inc., and Warner Jenkinson.

[0020] The formulation may contain additional pharmaceutically inactive substances. For example, it may contain one or more solubilizing agents, such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80. The formulation may also contain a dispersant, such as lecithin or glycerin. Collagen can also be added. Other additives include cyclodextrins, in particular alpha, beta, and gamma cyclodextrins. Also, vitamin E, particularly in solubilized form, or other antioxidants, including butylate hydroxyanisole (BHA) and butylate hydroxytoluene (BHT), may be added. Some additional examples of inactives follow: sodium chloride, cetrimide, thimerosal, benzalkonium chloride, boric acid, sodium carbonate, potassium chloride, propylene glycol, polyoxyethylene, polyoxypropylene, polyoxyl 40 stearate, polyvinyl alcohol, poloxamer 188, sodium citrate, sodium thiosulfate, sodium bisulfite, dextran 70, acetic acid, polyethylene glycol, povidone, dextrose, magnesium chloride, alginic acid, sodium acetate, sodium borate, edetate disodium, sodium hydroxide, and hydrochloric acid. The optimal amount of inactive ingredient

employed in the formulation can be conventionally determined based on the particular active pharmaceutical, and the intended use.

[0021] The formulation of the invention can be placed in any desired dispensing device suitable for an ophthalmic formulation. The device can be an ophthalmic delivery system such as a sterile ophthalmic tube, for example, a conventional 3.5-5 g tube having an ophthalmic tip and containing the ophthalmic formulation of the invention, or a sterile, single or daily use container containing 0.1-0.5 g of the formulation.

[0022] The pharmaceutical formulations can be administered via various routes including ocular instillation, subconjunctival administration, and intravitreal administration. A typical daily dose of pirenzepine may range 6 mg or less/whole body weight, preferably 4 mg or less/whole body weight, and can be administered in a single dose or in divided doses. However, it should be understood that the amount of pirenzepine actually administered ought to be determined in light of various relevant factors including the myopia to be treated, the chosen route of administration and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.

[0023] The stability data generated on the gel and solution dosage forms show the superiority of the gel over the solution in maintaining an acceptable physical appearance in the presence of the small amounts of the water-insoluble degradation product referred to in the background of the invention.

[0024] The following Examples are intended to further illustrate the scope of the invention without limiting its scope.

EXAMPLE 1

[0025] An aqueous ophthalmic gel of 2.0% pirenzepine for the treatment of myopia according to the present invention was prepared as follows:

Table 1. Pirenzepine ophthalmic gel formulations.

<u>Ingredient</u>	0.5% (in mg/g)	1.0% (in mg/g)	2.0% (in mg/g)
Pirenzepine dihydrochloride <i>(base equivalent)</i>	6.3 (5.0)	12.6 (10.0)	25.2 (20.0)
Hydroxypropyl Methyl-Cellulose (K100M, Dow Chemical Co.)	20	20	20
Sodium acetate	0.40	0.40	0.40
Benzalkonium chloride	0.05	0.05	0.05
Eddate disodium	0.15	0.15	0.15
Sodium chloride	5.0	3.5	0.0
Sodium Hydroxide (q.s. to pH)	5.0	5.0	5.0
Purified Water, q.s. to	1.00g	1.00g	1.00g

[0026] Part 1: Purified water was heated to 80-90°C. Hydroxypropyl methylcellulose (HPMC) was added and mixed until it was uniformly dispersed. The pH was adjusted to 5.0 ± 1.0 with sodium hydroxide, but this was not a critical step and can be eliminated. After being placed in a pressure vessel, the mixture was sterilized at 121°C for 30-45 minutes. In another embodiment, autoclaving is conducted under nitrogen when oxygen plays a role in viscosity loss upon autoclaving. The mixture was cooled to 25° to 30°C and mixed for several hours to yield a homogenous viscous gel. Batches manufactured in the appropriate jacketed pressure vessel showed that chilling Part 1 (the hydroxypropyl methylcellulose phase) to about 10°C rather than to 25° to 30°C after autoclaving greatly enhanced the hydration and consequently the viscosity of the gel. The gel was stored at 25° to 30°C for several hours to aid in dissolution and then maintained at 25° to 30°C for storage.

[0027] Part 2: The rest of the ingredients were mixed and dissolved in water until a clear solution was obtained. The pH was adjusted to 5.0 ± 1.0 with sodium hydroxide. The solution was sterilized by membrane filtration (0.2 microns).

[0028] The concentration of pirenzepine is calculated based on the free base. However, we added its dihydrochloride salt. By adjusting the pH to 5.0 ± 1.0 with sodium

hydroxide, the dihydrochloride salt is partially or completely converted to the monohydrochloride salt.

[0029] The solution of Part 2 was aseptically added to the gel of Part 1. Sufficient sterile water was added to q.s. to the final weight of the batch. A final pH adjustment was made, if necessary. The batch was mixed for about 48 hours to achieve homogeneity. A gel resulted that was used to aseptically fill pre-sterilized ophthalmic containers.

EXAMPLE 2

[0030] The ophthalmic pirenzepine gel preparation made in Example 1 was administered as follows (the ophthalmic tip of the dispensing mechanism did not touch any surface to avoid contamination). The lower lid of the eye to be administered was pulled down and a small amount of gel (approximately 0.25 inches) was applied to the inside of the eyelid. The gel was applied to the afflicted eye twice per day. A gel formulation in a target population of pediatric subjects was well tolerated.

EXAMPLE 3

[0031] Procedure for Viscosity Measurement: A Brookfield Cone and Plate Viscometer (Model RVDV-III+) was used to measure viscosity at about 20°C and shear rate of 1s^{-1} . The viscosities of 0.5 – 2 g samples of various gels were measured. Gels with viscosities of 5,000 to less than 600,000 cps were tested with a CP52 spindle, and other spindles are used depending on the viscosities of the gels.

[0032] While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, applications, and publications, referred to above, are hereby incorporated by reference.